Steven Prestrelski - 31 Jan 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: XERS
Reported as of: 31 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Feb 2023, 15:12:37 UTC
Prior SEC filing: 24 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht, as Attorney-in-Fact

Key filing fact

Steven Prestrelski filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 01 Feb 2023.

Key facts

This page summarizes Steven Prestrelski's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Feb 2023, 15:12.

Change

Previous filing in this sequence was filed on 24 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Award

Transaction value: $0
Shares: +150,000
Change %: +26%
Price: $0.000000
Shares after: 719,780
Date: 31 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.